氟伏沙明抗新型冠状病毒肺炎的作用可能由内皮型一氧化氮合酶介导。 - Suppr

Suppr

超能文献

Anti-SARS-CoV-2 Action of Fluvoxamine may be Mediated by Endothelial Nitric Oxide Synthase.

作者信息

Papadopoulos Konstantinos I, Sutheesophon Warachaya, Aw Tar-Choon

机构信息

THAI StemLife, Bangkok 10310, Thailand.

Department of Laboratory Medicine, Changi General Hospital, Singapore.

出版信息

Pharmacopsychiatry. 2022 Jan;55(1):57. doi: 10.1055/a-1641-0357. Epub 2021 Sep 23.

DOI:10.1055/a-1641-0357

PMID:34555857

Abstract

摘要

相似文献

Anti-SARS-CoV-2 Action of Fluvoxamine may be Mediated by Endothelial Nitric Oxide Synthase.

Pharmacopsychiatry. 2022 Jan;55(1):57. doi: 10.1055/a-1641-0357. Epub 2021 Sep 23.

Comment on: "Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence".

Drugs. 2022 Feb;82(3):349-351. doi: 10.1007/s40265-022-01682-7. Epub 2022 Feb 12.

Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence.

Drugs. 2021 Dec;81(18):2081-2089. doi: 10.1007/s40265-021-01636-5. Epub 2021 Dec 1.

Fluvoxamine for COVID-19?

Med Lett Drugs Ther. 2021 May 3;63(1623):69-70.

Authors' Reply to Mazza et al.: "Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence".

Drugs. 2022 Feb;82(3):353-354. doi: 10.1007/s40265-022-01681-8. Epub 2022 Feb 12.

Fluvoxamine for the treatment of COVID-19.

Lancet Glob Health. 2022 Mar;10(3):e330. doi: 10.1016/S2214-109X(22)00003-1.

Fluvoxamine for the treatment of COVID-19.

Lancet Glob Health. 2022 Mar;10(3):e331. doi: 10.1016/S2214-109X(21)00592-1.

Fluvoxamine for the treatment of COVID-19.

Lancet Glob Health. 2022 Mar;10(3):e332. doi: 10.1016/S2214-109X(22)00006-7.

Fluvoxamine and COVID-19.

WMJ. 2022;121:P2.

Fluvoxamine for the treatment of COVID-19 - Author's reply.

Lancet Glob Health. 2022 Mar;10(3):e333. doi: 10.1016/S2214-109X(21)00588-X.

引用本文的文献

A systematic review and meta-analysis, investigating dose and time of fluvoxamine treatment efficacy for COVID-19 clinical deterioration, death, and Long-COVID complications.

Sci Rep. 2024 Jun 12;14(1):13462. doi: 10.1038/s41598-024-64260-9.

Fluvoxamine Mediates Specific, Early, and Delayed SARS-CoV-2 Protection through Antioxidant and Cytoprotective Pathways via Sigma-1 Receptor Agonism.

Adv Pharm Bull. 2023 Jul;13(3):408-410. doi: 10.34172/apb.2023.045. Epub 2022 Sep 18.

Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies.

Acta Pharmacol Sin. 2023 Apr;44(4):695-709. doi: 10.1038/s41401-022-00998-0. Epub 2022 Oct 17.

Utility of NO and HS donating platforms in managing COVID-19: Rationale and promise.

Nitric Oxide. 2022 Nov 1;128:72-102. doi: 10.1016/j.niox.2022.08.003. Epub 2022 Aug 24.

Too hard to die: Exercise training mediates specific and immediate SARS-CoV-2 protection.

World J Virol. 2022 Mar 25;11(2):98-103. doi: 10.5501/wjv.v11.i2.98.

The influence of renin angiotensin aldosterone system (RAAS), endothelial nitric oxide synthase (eNOS) and erythropoietin (EPO) on COVID-19 complications.

Chem Biol Interact. 2022 Feb 25;354:109834. doi: 10.1016/j.cbi.2022.109834. Epub 2022 Jan 26.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验